Medindia

X

GVK BIO Enters into Drug Discovery Agreement With Wyeth Pharmaceuticals

by Thilaka Ravi on  May 26, 2008 at 3:11 PM Corporate News   - G J E 4
 GVK BIO Enters into Drug Discovery Agreement With Wyeth Pharmaceuticals
GVK BIO today announced its entry into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover drug candidates focused on pre-defined discovery targets.
Advertisement

GVK BIO will utilise in-house capabilities in discovery chemistry, informatics, biology and ADME to advance this program.

Advertisement
GVK BIO will be responsible for identifying drug candidates, which will be transferred to Wyeth to advance these compounds towards clinical studies.

Under the agreement, GVK BIO will receive an initial payment and will be eligible for success-based milestone payments.

G V Sanjay Reddy, Managing Director, GVK Biosciences said, "It is a momentous occasion for us. GVK BIO has had a successful partnership with Wyeth on various chemistry research activities dating to 2006.

This research agreement expands our work together and builds on GVK BIO's core strengths. This agreement further validates India's capability to do innovative research along with leading pharmaceutical and biotech companies".

Source: ANI
THK/L
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All